⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIOA News
BioAge Labs, Inc. Common Stock
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
BIOA
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China USA - English USA - English
prnewswire.com
BIOA
BIIB
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China USA - English USA - English
prnewswire.com
BIOA
BIIB
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
globenewswire.com
BIOA
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
globenewswire.com
BIOA
BioAge Announces Proposed Public Offering
globenewswire.com
BIOA
BioAge Announces Proposed Public Offering
globenewswire.com
BIOA
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
globenewswire.com
BIOA
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
globenewswire.com
BIOA
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
globenewswire.com
BIOA